Pharmaids Pharmaceuticals
- Market cap
- ₹ 101 Cr.
- P/E
- 112x
- P/B
- 2.09x
- 52-week range
- 25.6 – 53.9
- ROE
- −23%
- ROCE
- −15.5%
- Dividend yield
- 0%
- Debt / equity
- 0.49
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Pharmaids Pharmaceuticals Limited is an India-based suppliers of a range of specialty chemicals, skin care, hospital care and generic products in the areas of orthopedic, neuro and gastro, and other. The Company is engaged in the business of trading and manufacturing of generics, bulk drugs, and intermediaries, and other. The Company operates through Bulk Drugs and Intermediates segment. Its specialty chemicals products include Retinol, DL Alpha Tocopherol, D Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10 and D-Biotin. Its skin care products include Best care hands, Hands Sanitizer, Moisturizing Cream, Skinsure Plus, SkinSure Ultra, Alcohol Gel and Barrier Cream. Its hospital care products include Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen G, Strumen TRIACID, Facein Eco, Facein Power 256, Facein Spray, Sod Hypochlorite, Wipes and PPE. Its generic products include Linzomust, Benfoshine, Duojoint, and other.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Pharmaids Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)112 against a typical 34.6: pricier than most peers (1st = cheapest).197th of 220
- Sales growth−100% against a typical +15.6% from a year earlier.192nd of 197
- Share price, 3 months−9.9% against a typical −0.5%.143rd of 200
- Size₹ 100.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).148th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 6 | 1 | 3 | 0 |
| Expenses | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 6 | 11 | 5 | 4 | 1 |
| Operating Profit | −1 | −2 | −2 | −2 | −1 | −2 | −3 | −5 | −5 | −4 | −1 | −1 |
| OPM % | — | −12,150% | −18,000% | −1,011.8% | −137.4% | −143% | −2,069.2% | −435.7% | −76.7% | −442.2% | −40.2% | — |
| Other Income | −0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −1 | −2 | −2 | −2 | −1 | −2 | −4 | −6 | −2 | −4 | −2 | 3 |
| Tax % | −60.5% | −33.5% | 6.2% | −8.4% | −15.1% | −13.5% | −19.1% | −23.4% | −29.1% | −26.7% | −22.5% | 22.3% |
| Net Profit | −1 | −1 | −2 | −2 | −1 | −2 | −3 | −4 | −2 | −3 | −1 | 2 |
| EPS in Rs | −0.23 | −0.54 | −0.64 | −0.46 | −0.29 | −0.45 | −0.87 | −1.24 | −0.47 | −0.88 | −0.37 | 0.6 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 20%
- 5 Years
- 4%
- 3 Years
- —
- TTM
- 188%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −41%
- TTM
- −6%
- 10 Years
- 26%
- 5 Years
- 18%
- 3 Years
- −4%
- TTM
- —
- 10 Years
- −15%
- 5 Years
- −17%
- 3 Years
- −15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Pharmaids Pharmaceuticals | ₹ 27.31 | ₹ 101 Cr. | 112x | 2.1x | −23% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 27.1x | 2.6x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 82.1x | 16.1x | — | 21% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 24.5x | 4.4x | — | 28.6% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 49.7x | 1.4x | — | 13.2% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 35.6x | 5.7x | — | 15.5% |
Management
- Balagangadhara B C
- Chief Financial Officer
- Prasanna Subramanya Bhat
- Compliance Officer and Company Secretary
- Subhash Jain
- Executive and Non Independent Director
- S. Padmaja Kalyani
- Additional Non-Independent Executive Director
- Venu Madhava Kaparthys
- Whole-Time Director
- Mini Manikantans
- Whole Time Director
- S. Viswa Prasad
- Additional Non-Independent Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.